Development of a universal CTL-based vaccine for influenza
- PMID: 23337287
- PMCID: PMC3937198
- DOI: 10.4161/bioe.23573
Development of a universal CTL-based vaccine for influenza
Abstract
In pursuit of better influenza vaccines, many strategies are being studied worldwide. An attractive alternative is the generation of a broadly cross-reactive vaccine based on the induction of cytotoxic T-lymphocytes (CTL) directed against conserved internal antigens of influenza A virus. The feasibility of this approach using recombinant viral vectors has recently been demonstrated in mice and humans by several research groups. However, similar results might also be achieved through immunization with viral proteins expressed in a prokaryotic system formulated with the appropriate adjuvants and delivery systems. This approach would be much simpler and less expensive. Recent results from several laboratories seem to confirm this is as a valid option to be considered.
Keywords: adjuvants; cellular immunity; cross-presentation; cytotoxic-T-lymphocytes; influenza vaccines; recombinant antigen.
Similar articles
-
Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.Cell Immunol. 2001 Aug 1;211(2):143-53. doi: 10.1006/cimm.2001.1835. Cell Immunol. 2001. PMID: 11591118
-
Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant.Vaccine. 1992;10(5):309-18. doi: 10.1016/0264-410x(92)90369-u. Vaccine. 1992. PMID: 1349448
-
Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development.Virol J. 2010 Nov 30;7:351. doi: 10.1186/1743-422X-7-351. Virol J. 2010. PMID: 21118546 Free PMC article. Review.
-
Effective Respiratory CD8 T-Cell Immunity to Influenza Virus Induced by Intranasal Carbomer-Lecithin-Adjuvanted Non-replicating Vaccines.PLoS Pathog. 2016 Dec 20;12(12):e1006064. doi: 10.1371/journal.ppat.1006064. eCollection 2016 Dec. PLoS Pathog. 2016. PMID: 27997610 Free PMC article.
-
Development of a cytotoxic T-lymphocyte-based, broadly protective influenza vaccine.Microbiol Immunol. 2011 Jan;55(1):19-27. doi: 10.1111/j.1348-0421.2010.00273.x. Microbiol Immunol. 2011. PMID: 21175770 Review.
Cited by
-
Emerging adjuvants for intradermal vaccination.Int J Pharm. 2023 Feb 5;632:122559. doi: 10.1016/j.ijpharm.2022.122559. Epub 2022 Dec 28. Int J Pharm. 2023. PMID: 36586639 Free PMC article. Review.
-
Outer membrane vesicles harboring modified lipid A moiety augment the efficacy of an influenza vaccine exhibiting reduced endotoxicity in a mouse model.Vaccine. 2017 Jan 23;35(4):586-595. doi: 10.1016/j.vaccine.2016.12.025. Epub 2016 Dec 23. Vaccine. 2017. PMID: 28024958 Free PMC article.
-
Simultaneous CD8+ T-Cell Immune Response against SARS-Cov-2 S, M, and N Induced by Endogenously Engineered Extracellular Vesicles in Both Spleen and Lungs.Vaccines (Basel). 2021 Mar 10;9(3):240. doi: 10.3390/vaccines9030240. Vaccines (Basel). 2021. PMID: 33801926 Free PMC article.
-
A Recombinant Mosaic HAs Influenza Vaccine Elicits Broad-Spectrum Immune Response and Protection of Influenza a Viruses.Vaccines (Basel). 2024 Sep 2;12(9):1008. doi: 10.3390/vaccines12091008. Vaccines (Basel). 2024. PMID: 39340038 Free PMC article.
-
A mosaic influenza virus-like particles vaccine provides broad humoral and cellular immune responses against influenza A viruses.NPJ Vaccines. 2023 Sep 7;8(1):132. doi: 10.1038/s41541-023-00728-5. NPJ Vaccines. 2023. PMID: 37679361 Free PMC article.
References
-
- Dormitzer PR, Tsai TF, Del Giudice G. New technologies for influenza vaccines. Hum Vaccin Immunother. 2012;8:45–58. - PubMed
-
- Okamoto S, Matsuoka S, Takenaka N, Haredy AM, Tanimoto T, Gomi Y, et al. Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection. Clin Vaccine Immunol. 2012;19:979–90. doi: 10.1128/CVI.00016-12. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical